Gilead's remdesivir set to become Europe's first COVID-19 therapy

Gilead's remdesivir set to become Europe's first COVID-19 therapy

Since then, another phase 3 trial has shown that a five-day treatment course with remdesivir on top of standard care was more effective than standard care alone in moderately-ill patients, although strangely a 10-day course wasn't any better.

Dr. Umanath said that Tamil Nadu was the first State to distribute the drug to every district.

COVID-19 therapy by Covifor will cost less than 30,000 per patient.

AFP reports that at least two major USA studies have shown that remdesivir can reduce the duration of hospital stays for COVID-19 patients.

He further said that we are working closely with the government and the medical community so that public and private medical institutions across the country can quickly access the "COVIFOR" drug.

The EMA's human medicines committee (CHMP) is backing approval of Gilead's remdesivir - under the brand name Veklury - for the treatment of COVID-19 in patients aged 12 years and over with pneumonia who require supplemental oxygen. The next batch of the drug is to be shipped to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Kochi, Trivandrum and Goa.


The Union Ministry of Health has explained the use of Remdesivir as an investigational treatment antiviral drug in its latest clinical administration for COVID-19 patients.

The EMA endorsement means physicians can prescribe the Gilead drug in Europe once the European Commission, the EU executive, gives its approval, which is now a formality expected over the coming week. The investigational drug of Gilead Ramdesivir had also received an Emergency Use Authorization (EUA) from the US Food and Drug Administration (USFDA) for the treatment of critical COVID-19 hospitalized patients.

Not only in Europe, but the drug is now being used for treating severe COVID-19 cases in the US, India, Japan and South Korea.

In May, domestic pharma firms Hetero, Cipla and Jubilant Life Sciences entered into non-exclusive licensing agreements with drug major Gilead Sciences Inc for manufacturing and distribution of remdesivir.

A prior study in the US, headed by the National Institutes of Health recently discovered it provokes an average recovery period from 15 days to 11 times in hospitalized patients with acute illness.

Related:

Comments

Latest news

'It's something I will never forget': Stabbed Glasgow officer speaks of ordeal
Armed police officers attended the incident and I can confirm that a male suspect was shot by an armed officer. Police said the other five casualties remained in hospital, one of them in a critical condition.

Redmi 9A and Redmi 9C to debut on June 30, images leak
Although the Redmi 9A has been spotted multiple times on the rumor mill, the Redmi 9C has remained out of the spotlight. This distinct product will presumably switch the Redmi 8A as a person of the cheapest phones in Xiaomi's loved ones.

Starbucks pauses social media ads to fight against `hate speech`
The retailer will continue posting unpaid content on Facebook, which it said is its second-largest paid advertising platform. In June, the " Stop Hate for Profit " campaign was started by USA civil rights groups after the death of George Floyd .

Leicester could be set for localised lockdown following surge in cases
Sir Peter told the Today programme the city could "remain restricted for two weeks longer than the rest of the country". These were the details of the news United Kingdom could lockdown city of Leicester over virus fears for this day.

Twitter issues notice on Donald Trumps tweet warning against protesters
It was also reported that they spray-painted "BHAZ", which stands for "Black House Autonomous Zone", on the columns of St. This isn't the first time the social media platform has hidden one of the president's tweets behind a warning label.

Other news